[
  {
    "question": "Scenario of girl with dystonia, no Parkinsonism features.",
    "option_a": "DYT 1",
    "option_b": "DYT 5 ( GCH1 )",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Movement Disorders",
    "explanation": "Parkinson\u2019s disease (PD) is a neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons in the substantia nigra, leading to hallmark motor symptoms such as bradykinesia, rigidity, resting tremor, and postural instability. In early-stage PD, especially in younger patients, treatment decisions are individualized to balance symptomatic benefit with the potential long\u2010term side effects of medications. PD involves degeneration of dopamine\u2011producing neurons with resultant depletion of striatal dopamine. The pathological process is associated with the formation of Lewy bodies (aggregates of alpha-synuclein) and involves multiple mechanisms including mitochondrial dysfunction, oxidative stress, and protein misfolding. This underlies the clinical manifestations of the disease. Patients typically present with unilateral or asymmetrical motor symptoms initially, progressing to bilateral involvement as the disease advances. In younger patients, the strategy is often to delay the introduction of levodopa to reduce the risk of motor complications such as dyskinesia over time. The scenario alludes to an early treatment decision where starting levodopa (option A) may not be the optimal choice, and an alternative (option B) is preferred. Diagnosis is mostly clinical, supported by a history of progressive motor symptoms and a positive response to dopaminergic treatment. Differential diagnoses include drug\u2010induced parkinsonism, atypical parkinsonian syndromes (such as multiple system atrophy or progressive supranuclear palsy), and essential tremor. Ancillary testing like a DaTscan can be useful if the diagnosis is ambiguous. First-line management in early PD, especially in younger individuals, often favors a trial of dopamine agonists (or other non-levodopa options) to achieve symptomatic control while minimizing long-term levodopa complications. If symptoms worsen or in older patients, levodopa remains the gold standard. In pregnant or lactating patients, levodopa is generally considered relatively safe, but therapy should be individualized with close monitoring and weighing risks versus benefits. Option A (Start levodopa) might be more appropriate for older patients or in advanced disease, but in early PD in a younger patient, it may lead to earlier onset of levodopa-induced dyskinesia. Option B, which is assumed to represent an alternative first-line approach (such as initiating a dopamine agonist), is therefore the correct choice. Options C and D are not specified and do not alter this reasoning. 1. Younger PD patients benefit from delaying levodopa therapy to postpone motor complications. 2. Dopamine agonists are commonly used as first-line treatment in early PD for younger individuals. 3. The diagnosis of PD remains primarily clinical, with supportive imaging used in unclear cases. Recent guidelines and clinical studies emphasize individualized treatment in PD with a focus on quality of life. There is ongoing research into neuroprotective therapies and optimizing the timing of levodopa introduction, supporting the approach of using alternative agents in early disease management.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Orthostatic tremor not tolerating clonazepam, what is the second line?",
    "option_a": "Propranolol",
    "option_b": "Levodopa",
    "option_c": "Pramipexol",
    "option_d": "Trihexaphenydyl",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Movement Disorders",
    "explanation": "Parkinson\u2019s disease (PD) is a neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons in the substantia nigra, leading to hallmark motor symptoms such as bradykinesia, rigidity, resting tremor, and postural instability. In early-stage PD, especially in younger patients, treatment decisions are individualized to balance symptomatic benefit with the potential long\u2010term side effects of medications. PD involves degeneration of dopamine\u2011producing neurons with resultant depletion of striatal dopamine. The pathological process is associated with the formation of Lewy bodies (aggregates of alpha-synuclein) and involves multiple mechanisms including mitochondrial dysfunction, oxidative stress, and protein misfolding. This underlies the clinical manifestations of the disease. Patients typically present with unilateral or asymmetrical motor symptoms initially, progressing to bilateral involvement as the disease advances. In younger patients, the strategy is often to delay the introduction of levodopa to reduce the risk of motor complications such as dyskinesia over time. The scenario alludes to an early treatment decision where starting levodopa (option A) may not be the optimal choice, and an alternative (option B) is preferred. Diagnosis is mostly clinical, supported by a history of progressive motor symptoms and a positive response to dopaminergic treatment. Differential diagnoses include drug\u2010induced parkinsonism, atypical parkinsonian syndromes (such as multiple system atrophy or progressive supranuclear palsy), and essential tremor. Ancillary testing like a DaTscan can be useful if the diagnosis is ambiguous. First-line management in early PD, especially in younger individuals, often favors a trial of dopamine agonists (or other non-levodopa options) to achieve symptomatic control while minimizing long-term levodopa complications. If symptoms worsen or in older patients, levodopa remains the gold standard. In pregnant or lactating patients, levodopa is generally considered relatively safe, but therapy should be individualized with close monitoring and weighing risks versus benefits. Option A (Start levodopa) might be more appropriate for older patients or in advanced disease, but in early PD in a younger patient, it may lead to earlier onset of levodopa-induced dyskinesia. Option B, which is assumed to represent an alternative first-line approach (such as initiating a dopamine agonist), is therefore the correct choice. Options C and D are not specified and do not alter this reasoning. 1. Younger PD patients benefit from delaying levodopa therapy to postpone motor complications. 2. Dopamine agonists are commonly used as first-line treatment in early PD for younger individuals. 3. The diagnosis of PD remains primarily clinical, with supportive imaging used in unclear cases. Recent guidelines and clinical studies emphasize individualized treatment in PD with a focus on quality of life. There is ongoing research into neuroprotective therapies and optimizing the timing of levodopa introduction, supporting the approach of using alternative agents in early disease management.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Sydenham chorea treatment?",
    "option_a": "Haloperidol",
    "option_b": "Valproic acid",
    "option_c": "CMZ",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Sydenham chorea is a neurological disorder associated with acute rheumatic fever. It occurs as an autoimmune reaction post-group A streptococcal infection, leading to dysfunction of the basal ganglia. Its clinical presentation includes rapid, irregular, involuntary movements along with possible emotional and behavioral changes. The condition is thought to result from molecular mimicry; antibodies generated against streptococcal antigens cross-react with neuronal tissue in the basal ganglia. This immunologically mediated process produces the characteristic choreiform movements. Patients, typically children and adolescents, present with sudden onset chorea following a streptococcal infection. The movements are involuntary, rapid, and can affect the face, limbs, and trunk, sometimes accompanied by behavioral changes. A careful history including recent infections and evidence of rheumatic fever aids in diagnosis. Diagnosis is primarily clinical. Differential diagnoses include other causes of chorea such as drug-induced chorea, hereditary conditions (e.g., Huntington\u2019s disease), and metabolic disorders. Supporting evidence from a history of group A streptococcal infection and, if necessary, laboratory markers of inflammation or streptococcal antibodies, help solidify the diagnosis. The cornerstone of management includes antibiotic prophylaxis (usually with penicillin) to eradicate group A streptococcus and prevent recurrence of rheumatic fever. For symptomatic control of chorea, neuroleptics such as haloperidol are widely used. Haloperidol has demonstrated efficacy in reducing choreiform movements and is preferred, especially in cases where rapid symptom control is needed. In pregnancy and lactation, haloperidol is generally preferred over alternatives like valproic acid, which is teratogenic. Alternatives include valproic acid or carbamazepine, but these have limitations, particularly with regard to safety in pregnancy and lactation. Option A (Haloperidol) is a well-established treatment for symptomatic management of Sydenham chorea. Option B (Valproic acid) is used in some cases but carries teratogenic risks making it less favorable in women of childbearing potential. Option C (CMZ) is not clearly defined or standard in this context. Option D is blank, leaving no additional treatment option. \u2022 Always consider prophylactic antibiotic therapy to prevent recurrent group A streptococcal infections and further rheumatic fever episodes.  \u2022 In treating chorea, balance the need for efficacy with potential side effects; haloperidol remains a reliable first-line agent.  \u2022 For female patients who are pregnant or lactating, haloperidol is preferred over valproic acid due to teratogenic risks associated with the latter. Recent guidelines and clinical reviews continue to support the use of haloperidol for the symptomatic management of Sydenham chorea. Emerging evidence suggests that while alternative agents like valproic acid may be effective, their use is limited by safety concerns in women of reproductive age. Thus, haloperidol remains the most widely accepted treatment, particularly in scenarios where pregnancy and lactation are considerations.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "PD with dystonia, not improving with treatment.",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "\u2014representing an \u2018Unknown\u2019 or no universally effective treatment\u2014is correct because the literature and clinical experience underscore that some cases of PD",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Movement Disorders",
    "explanation": "Parkinson\u2019s disease (PD) is often complicated by dystonia, a movement disorder marked by sustained involuntary muscle contractions. In PD, dystonia may appear as an early manifestation, as an off\u2010state phenomenon, or as a complication of chronic dopaminergic therapy. The underlying principle is that the basal ganglia circuitry, when exposed to fluctuating dopamine levels, may generate abnormal motor output that manifests as dystonia. In PD, progressive degeneration of dopaminergic neurons leads to imbalances in the basal ganglia circuits. Levodopa therapy, while improving many motor symptoms, creates nonphysiologic, pulsatile stimulation of dopamine receptors. This erratic stimulation disrupts the normal sensorimotor integration, contributing to abnormal patterns of muscle contraction \u2013 i.e. dystonia. Studies continue to show that some PD-related dystonias are refractory to standard adjustments, reflecting complex underlying neurochemical changes. Clinically, PD patients with dystonia may experience painful, twisting movements affecting a focal region (e.g., foot cramp or neck spasm) or, in some cases, more generalized dystonia. The response to dopaminergic treatments is variable \u2013 while some patients may benefit from dosing adjustments or adjunctive therapies, others have dystonia that remains resistant to treatment. This variability reflects the multifaceted pathophysiology at work. In patients with PD, the diagnosis of dystonia relies on a thorough history and examination. Differential diagnoses include primary dystonia, drug\u2010induced dystonic reactions, or dystonic presentations of other Parkinson\u2010plus syndromes. A careful analysis of the timing of dystonic movements relative to medication dosing (eg, off-period vs. peak-dose dystonia) is essential. Management typically begins with optimizing levodopa dosing and scheduling (eg, dose fractionation). When these adjustments fail to improve dystonia, additional strategies (eg, botulinum toxin injections for focal dystonia or, in select cases, deep brain stimulation) may be considered. However, there is no one-size-fits-all remedy, which is reflected in the answer being \u2018Unknown\u2019 for a universally effective treatment. For pregnant or lactating patients with PD, levodopa is generally considered the most studied treatment; other options (such as botulinum toxin) have limited safety data and are used with caution. Option D\u2014representing an \u2018Unknown\u2019 or no universally effective treatment\u2014is correct because the literature and clinical experience underscore that some cases of PD-related dystonia remain refractory to standard interventions. Hypothetical alternatives such as simply increasing levodopa, adding anticholinergics, using botulinum toxin, or resorting to DBS each have limitations: increasing levodopa may worsen dyskinesia, anticholinergics have a narrow efficacy window and tolerability issues in older patients, botulinum toxin is effective for focal dystonia but not generalized forms, and DBS is invasive and not widely applicable. 1. Dystonia in PD may be related to both disease pathology and the effects of pulsatile levodopa stimulation. 2. Focal dystonia can sometimes be managed with botulinum toxin injections, but generalized cases may remain refractory. 3. Treatment must be individualized since no single intervention works for all patients. Recent research emphasizes the need for multimodal, individualized approaches to managing dystonia in PD. Studies and clinical guidelines highlight that while adjustments in levodopa dosing and adjunctive therapies (like botulinum toxin for focal symptoms) may be helpful, there remains a subset of patients for whom the optimal treatment strategy is uncertain.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "PD with motor function and dyskinesia.",
    "option_a": "Decrease sinemit and add dopamine agonist",
    "option_b": "",
    "option_c": "",
    "option_d": "\u2014representing an \u2018Unknown\u2019 or no universally effective treatment\u2014is correct because the literature and clinical experience underscore that some cases of PD",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Movement Disorders",
    "explanation": "Parkinson\u2019s disease (PD) is often complicated by dystonia, a movement disorder marked by sustained involuntary muscle contractions. In PD, dystonia may appear as an early manifestation, as an off\u2010state phenomenon, or as a complication of chronic dopaminergic therapy. The underlying principle is that the basal ganglia circuitry, when exposed to fluctuating dopamine levels, may generate abnormal motor output that manifests as dystonia. In PD, progressive degeneration of dopaminergic neurons leads to imbalances in the basal ganglia circuits. Levodopa therapy, while improving many motor symptoms, creates nonphysiologic, pulsatile stimulation of dopamine receptors. This erratic stimulation disrupts the normal sensorimotor integration, contributing to abnormal patterns of muscle contraction \u2013 i.e. dystonia. Studies continue to show that some PD-related dystonias are refractory to standard adjustments, reflecting complex underlying neurochemical changes. Clinically, PD patients with dystonia may experience painful, twisting movements affecting a focal region (e.g., foot cramp or neck spasm) or, in some cases, more generalized dystonia. The response to dopaminergic treatments is variable \u2013 while some patients may benefit from dosing adjustments or adjunctive therapies, others have dystonia that remains resistant to treatment. This variability reflects the multifaceted pathophysiology at work. In patients with PD, the diagnosis of dystonia relies on a thorough history and examination. Differential diagnoses include primary dystonia, drug\u2010induced dystonic reactions, or dystonic presentations of other Parkinson\u2010plus syndromes. A careful analysis of the timing of dystonic movements relative to medication dosing (eg, off-period vs. peak-dose dystonia) is essential. Management typically begins with optimizing levodopa dosing and scheduling (eg, dose fractionation). When these adjustments fail to improve dystonia, additional strategies (eg, botulinum toxin injections for focal dystonia or, in select cases, deep brain stimulation) may be considered. However, there is no one-size-fits-all remedy, which is reflected in the answer being \u2018Unknown\u2019 for a universally effective treatment. For pregnant or lactating patients with PD, levodopa is generally considered the most studied treatment; other options (such as botulinum toxin) have limited safety data and are used with caution. Option D\u2014representing an \u2018Unknown\u2019 or no universally effective treatment\u2014is correct because the literature and clinical experience underscore that some cases of PD-related dystonia remain refractory to standard interventions. Hypothetical alternatives such as simply increasing levodopa, adding anticholinergics, using botulinum toxin, or resorting to DBS each have limitations: increasing levodopa may worsen dyskinesia, anticholinergics have a narrow efficacy window and tolerability issues in older patients, botulinum toxin is effective for focal dystonia but not generalized forms, and DBS is invasive and not widely applicable. 1. Dystonia in PD may be related to both disease pathology and the effects of pulsatile levodopa stimulation. 2. Focal dystonia can sometimes be managed with botulinum toxin injections, but generalized cases may remain refractory. 3. Treatment must be individualized since no single intervention works for all patients. Recent research emphasizes the need for multimodal, individualized approaches to managing dystonia in PD. Studies and clinical guidelines highlight that while adjustments in levodopa dosing and adjunctive therapies (like botulinum toxin for focal symptoms) may be helpful, there remains a subset of patients for whom the optimal treatment strategy is uncertain.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Patient has PD and excessive sleep with motor fluctuation, what to give ?",
    "option_a": "Selegeline",
    "option_b": "",
    "option_c": "",
    "option_d": "\u2014representing an \u2018Unknown\u2019 or no universally effective treatment\u2014is correct because the literature and clinical experience underscore that some cases of PD",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Movement Disorders",
    "explanation": "Parkinson\u2019s disease (PD) is often complicated by dystonia, a movement disorder marked by sustained involuntary muscle contractions. In PD, dystonia may appear as an early manifestation, as an off\u2010state phenomenon, or as a complication of chronic dopaminergic therapy. The underlying principle is that the basal ganglia circuitry, when exposed to fluctuating dopamine levels, may generate abnormal motor output that manifests as dystonia. In PD, progressive degeneration of dopaminergic neurons leads to imbalances in the basal ganglia circuits. Levodopa therapy, while improving many motor symptoms, creates nonphysiologic, pulsatile stimulation of dopamine receptors. This erratic stimulation disrupts the normal sensorimotor integration, contributing to abnormal patterns of muscle contraction \u2013 i.e. dystonia. Studies continue to show that some PD-related dystonias are refractory to standard adjustments, reflecting complex underlying neurochemical changes. Clinically, PD patients with dystonia may experience painful, twisting movements affecting a focal region (e.g., foot cramp or neck spasm) or, in some cases, more generalized dystonia. The response to dopaminergic treatments is variable \u2013 while some patients may benefit from dosing adjustments or adjunctive therapies, others have dystonia that remains resistant to treatment. This variability reflects the multifaceted pathophysiology at work. In patients with PD, the diagnosis of dystonia relies on a thorough history and examination. Differential diagnoses include primary dystonia, drug\u2010induced dystonic reactions, or dystonic presentations of other Parkinson\u2010plus syndromes. A careful analysis of the timing of dystonic movements relative to medication dosing (eg, off-period vs. peak-dose dystonia) is essential. Management typically begins with optimizing levodopa dosing and scheduling (eg, dose fractionation). When these adjustments fail to improve dystonia, additional strategies (eg, botulinum toxin injections for focal dystonia or, in select cases, deep brain stimulation) may be considered. However, there is no one-size-fits-all remedy, which is reflected in the answer being \u2018Unknown\u2019 for a universally effective treatment. For pregnant or lactating patients with PD, levodopa is generally considered the most studied treatment; other options (such as botulinum toxin) have limited safety data and are used with caution. Option D\u2014representing an \u2018Unknown\u2019 or no universally effective treatment\u2014is correct because the literature and clinical experience underscore that some cases of PD-related dystonia remain refractory to standard interventions. Hypothetical alternatives such as simply increasing levodopa, adding anticholinergics, using botulinum toxin, or resorting to DBS each have limitations: increasing levodopa may worsen dyskinesia, anticholinergics have a narrow efficacy window and tolerability issues in older patients, botulinum toxin is effective for focal dystonia but not generalized forms, and DBS is invasive and not widely applicable. 1. Dystonia in PD may be related to both disease pathology and the effects of pulsatile levodopa stimulation. 2. Focal dystonia can sometimes be managed with botulinum toxin injections, but generalized cases may remain refractory. 3. Treatment must be individualized since no single intervention works for all patients. Recent research emphasizes the need for multimodal, individualized approaches to managing dystonia in PD. Studies and clinical guidelines highlight that while adjustments in levodopa dosing and adjunctive therapies (like botulinum toxin for focal symptoms) may be helpful, there remains a subset of patients for whom the optimal treatment strategy is uncertain.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "In PSP receiving sinemit what will improve?",
    "option_a": "Rigidity",
    "option_b": "Bradykinesia",
    "option_c": "",
    "option_d": "\u2014representing an \u2018Unknown\u2019 or no universally effective treatment\u2014is correct because the literature and clinical experience underscore that some cases of PD",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Movement Disorders",
    "explanation": "Parkinson\u2019s disease (PD) is often complicated by dystonia, a movement disorder marked by sustained involuntary muscle contractions. In PD, dystonia may appear as an early manifestation, as an off\u2010state phenomenon, or as a complication of chronic dopaminergic therapy. The underlying principle is that the basal ganglia circuitry, when exposed to fluctuating dopamine levels, may generate abnormal motor output that manifests as dystonia. In PD, progressive degeneration of dopaminergic neurons leads to imbalances in the basal ganglia circuits. Levodopa therapy, while improving many motor symptoms, creates nonphysiologic, pulsatile stimulation of dopamine receptors. This erratic stimulation disrupts the normal sensorimotor integration, contributing to abnormal patterns of muscle contraction \u2013 i.e. dystonia. Studies continue to show that some PD-related dystonias are refractory to standard adjustments, reflecting complex underlying neurochemical changes. Clinically, PD patients with dystonia may experience painful, twisting movements affecting a focal region (e.g., foot cramp or neck spasm) or, in some cases, more generalized dystonia. The response to dopaminergic treatments is variable \u2013 while some patients may benefit from dosing adjustments or adjunctive therapies, others have dystonia that remains resistant to treatment. This variability reflects the multifaceted pathophysiology at work. In patients with PD, the diagnosis of dystonia relies on a thorough history and examination. Differential diagnoses include primary dystonia, drug\u2010induced dystonic reactions, or dystonic presentations of other Parkinson\u2010plus syndromes. A careful analysis of the timing of dystonic movements relative to medication dosing (eg, off-period vs. peak-dose dystonia) is essential. Management typically begins with optimizing levodopa dosing and scheduling (eg, dose fractionation). When these adjustments fail to improve dystonia, additional strategies (eg, botulinum toxin injections for focal dystonia or, in select cases, deep brain stimulation) may be considered. However, there is no one-size-fits-all remedy, which is reflected in the answer being \u2018Unknown\u2019 for a universally effective treatment. For pregnant or lactating patients with PD, levodopa is generally considered the most studied treatment; other options (such as botulinum toxin) have limited safety data and are used with caution. Option D\u2014representing an \u2018Unknown\u2019 or no universally effective treatment\u2014is correct because the literature and clinical experience underscore that some cases of PD-related dystonia remain refractory to standard interventions. Hypothetical alternatives such as simply increasing levodopa, adding anticholinergics, using botulinum toxin, or resorting to DBS each have limitations: increasing levodopa may worsen dyskinesia, anticholinergics have a narrow efficacy window and tolerability issues in older patients, botulinum toxin is effective for focal dystonia but not generalized forms, and DBS is invasive and not widely applicable. 1. Dystonia in PD may be related to both disease pathology and the effects of pulsatile levodopa stimulation. 2. Focal dystonia can sometimes be managed with botulinum toxin injections, but generalized cases may remain refractory. 3. Treatment must be individualized since no single intervention works for all patients. Recent research emphasizes the need for multimodal, individualized approaches to managing dystonia in PD. Studies and clinical guidelines highlight that while adjustments in levodopa dosing and adjunctive therapies (like botulinum toxin for focal symptoms) may be helpful, there remains a subset of patients for whom the optimal treatment strategy is uncertain.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Tic and ADHD:",
    "option_a": "Atomxtine",
    "option_b": "Methylphenidate",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "ADHD and tic disorders frequently coexist. In managing children with both tics and ADHD, choosing a medication that minimizes the risk of exacerbating tics is essential. Atomoxetine, a non\u2010stimulant selective norepinephrine reuptake inhibitor, is commonly considered because it is less likely to worsen tic symptoms than traditional stimulants. ADHD is characterized by dysregulation of dopaminergic and noradrenergic pathways in the prefrontal cortex, while tic disorders are associated with abnormal basal ganglia circuitry and dopaminergic hyperactivity. Atomoxetine increases norepinephrine levels without the same degree of dopaminergic stimulation seen with stimulants, thus reducing the risk of tic exacerbation. In clinical practice, patients with ADHD and coexisting tic disorders require treatment that improves attention and behavior without increasing tic frequency or severity. Although stimulants (like methylphenidate) are first\u2010line for ADHD, concerns about motor tics prompt many clinicians to opt for non-stimulant options like atomoxetine in these comorbid cases. Diagnosis is based on clinical assessment. Differential diagnoses include ADHD without tics, primary tic disorders (such as Tourette syndrome alone), and anxiety disorders. A careful history and observation help differentiate by noting the timing and triggers of tics relative to medication use. Current guidelines suggest that while stimulants remain highly effective for ADHD, in cases complicated by tics clinicians may choose atomoxetine or alpha-2 agonists (like guanfacine or clonidine) to minimize tic exacerbation. In pregnancy and lactation, both atomoxetine and stimulants must be used with caution. Levetiracetam and non-pharmacologic interventions (behavioral therapy) may also be considered, with risk\u2013benefit discussions and close maternal\u2013fetal monitoring. Option A (Atomoxetine) is correct because it is known to treat ADHD without significantly worsening tics. Option B (Methylphenidate) is effective for ADHD, but there has been traditional concern about tic exacerbation even though recent evidence suggests it may be used carefully; however, in exam scenarios, atomoxetine is favored in this setting. Options C and D are not provided. 1. Atomoxetine is a preferred non-stimulant option in ADHD patients with comorbid tic disorders. 2. Despite historical concerns, recent studies show that stimulants may not universally worsen tics, but caution is advised. 3. A tailored treatment plan based on patient-specific factors is essential. Recent systematic reviews and clinical guidelines suggest that while stimulants can be used safely in many patients with tics, non-stimulants such as atomoxetine remain an excellent choice in cases where tic worsening is a concern. Current research emphasizes personalized treatment planning, considering both behavioral and pharmacologic therapies.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Patient with HTN, DM with hx of CABG; presented with bilateral lower limbs slowing, and parkinsonism; MRI leukoariosis and hydrocephalus exvacu, what you will do?",
    "option_a": "VP shunt",
    "option_b": "treat his vascular risk factors",
    "option_c": "start levodopa",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Movement Disorders",
    "explanation": "This patient presents with features that could be attributed to vascular parkinsonism rather than idiopathic Parkinson\u2019s disease or normal pressure hydrocephalus (NPH). Vascular parkinsonism is often seen in patients with vascular risk factors, and MRI findings such as leukoaraiosis support this diagnosis. Vascular parkinsonism results from chronic small vessel ischemic changes, particularly in the subcortical white matter and basal ganglia, leading to impaired motor function. Hydrocephalus ex vacuo represents ventricular enlargement secondary to brain atrophy rather than CSF accumulation from an obstruction, and therefore it is not amenable to shunting. In this scenario, the patient\u2019s bilateral lower limb slowing and parkinsonian features, along with his background of hypertension, diabetes, and previous CABG, point toward vascular parkinsonism. MRI findings of leukoaraiosis and hydrocephalus ex vacuo further support a vascular etiology rather than a shunt-responsive condition like NPH. Key differentials include normal pressure hydrocephalus (NPH), idiopathic Parkinson\u2019s disease, and vascular parkinsonism. NPH is characterized by a triad (gait disturbance, urinary incontinence, cognitive decline) and ventriculomegaly out of proportion to cortical atrophy. In contrast, vascular parkinsonism is associated with white matter changes (leukoaraiosis) and a poor response to levodopa. The primary management strategy for vascular parkinsonism involves aggressive treatment of vascular risk factors (blood pressure, diabetes, cholesterol) and implementation of lifestyle modifications. Pharmacologic treatments (e.g., levodopa) are less effective compared to idiopathic Parkinson\u2019s disease. In addition, physical therapy can be helpful. In pregnancy or lactation, management of vascular risk factors requires careful monitoring of medication safety and appropriate adjustments per current obstetric guidelines. Option A (VP shunt) is inappropriate because hydrocephalus ex vacuo does not benefit from shunting. Option B (treat his vascular risk factors) is correct as addressing these factors is the mainstay of management in vascular parkinsonism. Option C (start levodopa) is usually ineffective in vascular parkinsonism compared to idiopathic Parkinson\u2019s disease. 1. Vascular parkinsonism is common in patients with multiple vascular risk factors and is characterized predominantly by lower body motor deficits. 2. Hydrocephalus ex vacuo is a sign of brain atrophy and is not an indication for VP shunt. 3. Control of vascular risk factors is crucial to prevent further progression. Recent clinical guidelines emphasize the importance of secondary prevention in patients with vascular parkinsonism. Studies indicate that while levodopa has limited efficacy, a multidisciplinary approach including vascular risk management and rehabilitation is key. Imaging techniques continue to be refined for better differentiation between vascular parkinsonism and NPH.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "pt came with Parkinson hd increase dyskinesia + parkinsonism he is on Levodopa100/25 Q6h, what to do:",
    "option_a": "decrease levodopa and increase DA",
    "option_b": "increase Levodopa and add amantadine",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Parkinson\u2019s disease patients on levodopa therapy may develop motor complications over time including dyskinesia (involuntary, often hyperkinetic movements) alongside persistent parkinsonian symptoms. The therapeutic goal is to balance \u201con\u201d time with optimal motor control while minimizing dyskinesia. Levodopa-induced dyskinesia is thought to result from pulsatile stimulation of dopamine receptors due to the short half-life of levodopa combined with progressive loss of dopaminergic neurons. This leads to postsynaptic receptor sensitization and abnormal motor responses. Reducing peak doses can help diminish peak-dose dyskinesia, while adding a dopamine agonist may provide a steadier dopaminergic effect. In clinical practice, patients may present with increased dyskinetic movements along with parkinsonian symptoms despite frequent dosing. This juxtaposition suggests that the current regimen is causing high fluctuations in dopamine levels, resulting in both periods of excessive and insufficient dopaminergic stimulation. It is important to differentiate between dyskinesia due to overmedication (peak-dose dyskinesia) and the wearing-off phenomenon. A thorough review of the patient\u2019s medication dosing schedule, symptom timing, and response is essential. Other differentials may include motor fluctuations that can occur with advanced Parkinson\u2019s disease. A tiered management approach involves: 1) Adjusting the levodopa dosing regimen by reducing the individual dose and/or increasing dosing frequency to achieve smoother plasma concentrations. 2) Adding or increasing a dopamine agonist to maintain dopaminergic stimulation, thereby reducing the reliance on high-levedopa doses. 3) Considering adjuvant therapies such as amantadine, which has evidence for reducing dyskinesia. In pregnancy and lactation, levodopa is generally preferred due to a relatively better-known safety profile, and any introduction of dopamine agonists requires careful risk-benefit evaluation. Option A (decrease levodopa and increase dopamine agonist) is correct because it aims to smooth out the peaks and troughs in dopamine levels, reducing dyskinesia while trying to maintain adequate symptomatic control. Option B (increase levodopa and add amantadine) would likely worsen dyskinesia by further boosting peak levels, although amantadine can reduce dyskinesia; increasing levodopa is generally contraindicated in this context. Options C and D are not provided. 1. Levodopa-induced dyskinesia is a sign of long-term PD therapy and requires careful medication adjustment. 2. A shift to a more continuous dopaminergic stimulation strategy can mitigate motor complications. 3. Amantadine is an effective adjunct for reducing dyskinesia but should not be accompanied by an increase in levodopa dosage. Recent studies support a strategy that minimizes pulsatile dopaminergic stimulation by either modifying levodopa dosing or using adjunct medications. Guidelines recommend personalized therapy adjustments, and while newer agents are under investigation, dopamine agonists remain a cornerstone of therapy when dyskinesia is problematic.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Parkinson patient on medication developed wearing off phenomena; what is the mechanism?",
    "option_a": "Failure medication",
    "option_b": "Disease progression",
    "option_c": "medication intolerance",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Movement Disorders",
    "explanation": "The wearing-off phenomenon in Parkinson\u2019s disease refers to the gradual shortening of the duration of benefit from each dose of levodopa, leading to the re-emergence of motor symptoms before the next dose is due. With the progression of Parkinson\u2019s disease, there is ongoing loss of dopaminergic neurons in the substantia nigra. This loss reduces the buffering capacity of dopamine in the striatum, leading to a decreased reservoir of dopamine. As a result, the effects of levodopa wear off more quickly. It is a manifestation of disease progression rather than a failure of the medication itself or medication intolerance. Clinically, patients may notice that the time during which their symptoms are controlled by a dose of levodopa shortens over time. This often coincides with the advancement of Parkinson\u2019s disease, and adjustments in medication timing and dosage become necessary. Diagnosis is based on the patient\u2019s clinical history and the temporal correlation between medication dosing and symptom recurrence. Differential diagnoses include motor fluctuations such as dyskinesias and other causes of reduced drug efficacy. Detailed patient logs and, in some cases, pharmacokinetic studies help clarify the cause. Management involves strategies to provide more continuous dopaminergic stimulation. First-line measures include adjusting the timing of levodopa doses, using controlled-release formulations, or adding adjuvant medications such as COMT inhibitors (e.g., entacapone) or MAO-B inhibitors (e.g., selegiline). In pregnancy and lactation, treatment modifications must be undertaken carefully, as levodopa is generally preferred due to the most extensive safety data, while other agents have less evidence for fetal safety. Option A (Failure medication) is incorrect because the medication is still effective but its duration of action is reduced. Option B (Disease progression) is correct because the wearing-off phenomenon principally reflects the advancement of neurodegeneration and the loss of endogenous dopamine storage capacity. Option C (Medication intolerance) is incorrect because intolerance would manifest as adverse effects rather than a predictable shortening of benefit. 1. The wearing-off phenomenon is a common indicator of the natural progression of Parkinson\u2019s disease. 2. Adjusting the dosing schedule and using adjunct therapies can help manage these motor fluctuations. 3. Continuous dopaminergic stimulation remains the therapeutic goal to minimize wearing-off effects. Recent research highlights the benefits of using adjunctive therapies (COMT inhibitors, MAO-B inhibitors, dopamine agonists) to smooth out levodopa plasma levels and reduce motor fluctuations. Long-term studies continue to support that wearing-off is primarily due to disease progression rather than a change in the medication\u2019s inherent efficacy.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Parkinson patient came with increase hallucination and memory loss, what is the Rx?",
    "option_a": "Rivastigmin",
    "option_b": "clozapine",
    "option_c": "quetiapin",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "In Parkinson\u2019s disease (PD), many patients eventually develop cognitive decline (Parkinson\u2019s disease dementia) and can experience visual hallucinations. The core idea is that cholinergic deficits secondary to PD pathology contribute to memory loss and psychosis. Rivastigmine, a cholinesterase inhibitor, is approved for use in PD dementia as it helps improve cognition by increasing acetylcholine levels. PD dementia arises from the progressive loss of dopaminergic neurons as well as cholinergic deficits in the cortex. Lewy body deposition and alpha\u2010synuclein pathology lead to impaired neurotransmission. Rivastigmine works by inhibiting acetylcholinesterase, thereby increasing acetylcholine in the synaptic cleft, which can improve cognitive symptoms and may even mitigate hallucinations in some patients. Patients with PD dementia usually present with memory impairment, slowed thought processes, and visual hallucinations. The overlap of motor symptoms with cognitive decline requires careful management because many psychotropic agents may worsen motor function. In this scenario, the patient\u2019s increase in hallucinations and memory loss is typical of PD dementia. The diagnosis of PD dementia is clinical. The differential includes Alzheimer\u2019s disease (which usually presents without prominent parkinsonian features early on) and Dementia with Lewy Bodies (which is often differentiated by the timing of motor versus cognitive symptoms). Detailed patient history, cognitive assessments, and, if needed, neuroimaging help differentiate among these conditions. First\u2010line treatment for PD dementia is cholinesterase inhibitors, with rivastigmine having specific FDA approval. If psychotic symptoms are severe and persist despite cholinesterase inhibitors, low\u2010dose atypical antipsychotics (like quetiapine or clozapine with careful monitoring) may be used. Although PD largely affects older adults, in cases where pregnancy or lactation is a concern (rare in PD), the benefits and risks must be weighed due to limited data in these populations. Option A (Rivastigmine) is correct because it addresses both the cognitive decline and may help stabilize hallucinations. Option B (Clozapine) and Option C (Quetiapine) are both atypical antipsychotics that can be used to treat psychosis in PD but do not improve memory loss and carry risks (e.g., agranulocytosis for clozapine and sedation with quetiapine) that make them second\u2010line choices in this scenario. 1. Rivastigmine is the only cholinesterase inhibitor specifically FDA approved for Parkinson\u2019s disease dementia. 2. Cholinergic deficits in PD are a major contributor to cognitive decline and hallucinations. 3. Avoid typical antipsychotics in PD due to the risk of exacerbating motor symptoms. Recent randomized controlled trials and practice guidelines continue to support the role of cholinesterase inhibitors in PD dementia. Studies indicate that rivastigmine can modestly improve cognitive outcomes and may reduce behavioral symptoms, with its use being well established in clinical practice.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Same scenario asking about diagnosis:",
    "option_a": "Fragile X.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "In Parkinson\u2019s disease (PD), many patients eventually develop cognitive decline (Parkinson\u2019s disease dementia) and can experience visual hallucinations. The core idea is that cholinergic deficits secondary to PD pathology contribute to memory loss and psychosis. Rivastigmine, a cholinesterase inhibitor, is approved for use in PD dementia as it helps improve cognition by increasing acetylcholine levels. PD dementia arises from the progressive loss of dopaminergic neurons as well as cholinergic deficits in the cortex. Lewy body deposition and alpha\u2010synuclein pathology lead to impaired neurotransmission. Rivastigmine works by inhibiting acetylcholinesterase, thereby increasing acetylcholine in the synaptic cleft, which can improve cognitive symptoms and may even mitigate hallucinations in some patients. Patients with PD dementia usually present with memory impairment, slowed thought processes, and visual hallucinations. The overlap of motor symptoms with cognitive decline requires careful management because many psychotropic agents may worsen motor function. In this scenario, the patient\u2019s increase in hallucinations and memory loss is typical of PD dementia. The diagnosis of PD dementia is clinical. The differential includes Alzheimer\u2019s disease (which usually presents without prominent parkinsonian features early on) and Dementia with Lewy Bodies (which is often differentiated by the timing of motor versus cognitive symptoms). Detailed patient history, cognitive assessments, and, if needed, neuroimaging help differentiate among these conditions. First\u2010line treatment for PD dementia is cholinesterase inhibitors, with rivastigmine having specific FDA approval. If psychotic symptoms are severe and persist despite cholinesterase inhibitors, low\u2010dose atypical antipsychotics (like quetiapine or clozapine with careful monitoring) may be used. Although PD largely affects older adults, in cases where pregnancy or lactation is a concern (rare in PD), the benefits and risks must be weighed due to limited data in these populations. Option A (Rivastigmine) is correct because it addresses both the cognitive decline and may help stabilize hallucinations. Option B (Clozapine) and Option C (Quetiapine) are both atypical antipsychotics that can be used to treat psychosis in PD but do not improve memory loss and carry risks (e.g., agranulocytosis for clozapine and sedation with quetiapine) that make them second\u2010line choices in this scenario. 1. Rivastigmine is the only cholinesterase inhibitor specifically FDA approved for Parkinson\u2019s disease dementia. 2. Cholinergic deficits in PD are a major contributor to cognitive decline and hallucinations. 3. Avoid typical antipsychotics in PD due to the risk of exacerbating motor symptoms. Recent randomized controlled trials and practice guidelines continue to support the role of cholinesterase inhibitors in PD dementia. Studies indicate that rivastigmine can modestly improve cognitive outcomes and may reduce behavioral symptoms, with its use being well established in clinical practice.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Pediatric patient had mental retardationa and tremor and ataxia; his sister had ovarian insufficiency what is the typical image finding:",
    "option_a": "bilateral cerebellar hyperintensity",
    "option_b": "Elongated medulla.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "This case describes a pediatric patient with intellectual disability accompanied by tremor and ataxia, along with a family history in a sister of ovarian insufficiency. This constellation of neurological and endocrine findings is seen in FMR1 gene\u2013related disorders. In fragile X syndrome, the full mutation causes intellectual disability in affected males, while the premutation state in females is associated with Fragile X-associated primary ovarian insufficiency (FXPOI) and in some male premutation carriers with Fragile X\u2013associated tremor/ataxia syndrome (FXTAS), where characteristic MRI findings are encountered. Mutations in the FMR1 gene result either in a full mutation (typically >200 CGG repeats), causing fragile X syndrome with intellectual disability, or in a premutation (55\u2013200 repeats) state, where elevated levels of FMR1 mRNA lead to a toxic gain\u2010of\u2010function. This toxicity can cause intranuclear inclusions and white matter degeneration, especially in the cerebellar regions (including the middle cerebellar peduncles), which underlies the tremor and ataxia seen in FXTAS. Affected males with a full mutation present with intellectual disability and behavioral issues, while premutation carriers can develop a late-onset tremor/ataxia syndrome (FXTAS). In females, premutation carriers are at risk for ovarian insufficiency (FXPOI), which explains the sister\u2019s presentation. Although FXTAS typically occurs in older adults, the overlapping features in FMR1-related disorders can bridge childhood intellectual deficits with later-onset movement disorders in the same family. Assessment should include a thorough clinical history and neurological examination, with emphasis on family history of both cognitive and reproductive dysfunction. Brain MRI is a key diagnostic tool; the typical finding in FXTAS is symmetric T2/FLAIR hyperintensity in the middle cerebellar peduncles (often described more generally as bilateral cerebellar white matter hyperintensity). Differential diagnoses include other causes of cerebellar ataxia (such as spinocerebellar ataxias or ataxia\u2010telangiectasia), but the ovarian insufficiency in the family is a crucial clue toward an FMR1-related disorder. Confirmatory diagnosis is made by genetic testing for CGG repeat expansions in the FMR1 gene. There is no curative treatment for these disorders; management is primarily supportive and symptom based. In FXTAS, treatment may involve medications for tremor, physical therapy for ataxia, and cognitive support. Genetic counseling is essential for family planning and for discussing the risk of transmission. For women with FXPOI (including those who are pregnant or lactating), current guidelines stress multidisciplinary management that includes endocrine and obstetrical evaluation, as well as discussion of reproductive options given the risk of fragile X syndrome in offspring. Lactation is generally not contraindicated, but careful endocrinologic follow\u2010up is warranted. Option A, 'bilateral cerebellar hyperintensity', refers to the characteristic MRI finding seen in FXTAS, specifically the hyperintensity in the middle cerebellar peduncles. Option B (elongated medulla) is not a finding associated with FMR1-related disorders. The absence of additional options further supports Option A as the correct answer. \u2022 In families with known FMR1 mutations, note that males may manifest with intellectual disability while female carriers are at risk for ovarian insufficiency. \n\u2022 The MRI 'MCP sign' (bilateral T2 hyperintensity in the middle cerebellar peduncles) is a key radiologic marker for FXTAS. \n\u2022 Although FXTAS typically presents later in life, overlap in symptomatology in FMR1-related disorders can be observed within the same family. Recent clinical studies and guidelines emphasize the importance of early genetic testing in families with suggestive histories, as well as the use of brain MRI to detect white matter changes. Current management is symptomatic, and emerging research is focused on better understanding the molecular cascades underlying FMR1 toxicity in hopes of developing targeted therapies. In pregnant or lactating patients who are carriers, multidisciplinary approaches including genetic counseling remain a central part of care.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Pediatric patient had mental retardation and tremor and ataxia; his sister had ovarian insufficiency what is the typical image finding:",
    "option_a": "bilateral cerebellar hyperintensity",
    "option_b": "Elongated medulla.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "This case describes a pediatric patient with intellectual disability, tremor, and ataxia whose sister has ovarian insufficiency. This constellation of neurological symptoms in a boy together with ovarian failure in a female sibling is highly suggestive of an eIF2B-related leukodystrophy \u2013 often termed ovarioleukodystrophy or vanishing white matter disease. In these disorders, a mutation in the eIF2B gene causes dysfunction in the cellular stress response, particularly affecting white matter (including the cerebellum). Mutations in the eIF2B gene impair the regulation of protein synthesis during cellular stress, leading to a selective vulnerability of oligodendrocytes that maintain myelin. The resultant demyelination and white matter degeneration can be visualized as abnormal signal intensities on MRI. When the cerebellum is involved, T2-weighted images may show bilateral hyperintensities, reflecting areas of demyelination and gliosis. Clinically, affected children often present with a combination of motor difficulties (tremor, ataxia) and cognitive impairment. In female relatives, the association of premature ovarian failure or ovarian insufficiency is a key clue. Even though males do not exhibit ovarian dysfunction, the familial occurrence supports an autosomal recessive inheritance pattern, as seen in eIF2B-related disorders. The work-up requires a high index of suspicion when a neurologically impaired child has a family history suggestive of endocrine dysfunction (ovarian insufficiency). Brain MRI is the imaging modality of choice \u2013 demonstrating diffuse white matter abnormalities with T2 hyperintensities, particularly in the cerebellum. Differential imaging evaluation may include other leukodystrophies (e.g., metachromatic leukodystrophy or adrenoleukodystrophy), but the specific association with ovarian failure directs the suspicion to eIF2B mutations. Genetic testing can confirm the diagnosis. Management is largely supportive as no curative treatment exists. Approaches include physical and occupational therapy to manage ataxia and tremor. For female patients or carriers, monitoring and endocrine evaluation are advised. Hormone replacement therapy (HRT) may be considered in the context of premature ovarian insufficiency, with careful consideration of pregnancy and lactation: any hormonal management must be tailored to the individual\u2019s reproductive plans and guided by current endocrine and obstetrical recommendations. In addition, stressors (such as febrile illnesses or head trauma) should be minimized because they may precipitate neurological deterioration. Option A, 'bilateral cerebellar hyperintensity', is consistent with the expected T2-weighted MRI findings in eIF2B-related leukodystrophy, particularly where cerebellar involvement is noted. Option B, 'Elongated medulla', is not a typical or specific finding in this condition. With options C and D missing, the marked answer (A) aligns best with the known imaging characteristics of this disorder. \u2022 In a pediatric patient with ataxia and tremor, always consider a leukodystrophy in the differential, especially when there is a family history of ovarian dysfunction. \u2022 eIF2B-related disorders should be suspected when neurodegeneration is accompanied by endocrine abnormalities. \u2022 MRI findings of bilateral cerebellar (and often diffuse white matter) T2 hyperintensities are highly suggestive of this diagnosis. \u2022 Early diagnosis allows for appropriate supportive interventions and genetic counseling. Recent literature reaffirms that eIF2B mutations lead to a range of clinical phenotypes, unified by the characteristic deterioration of white matter seen on MRI. Current research is focused on understanding the molecular pathways involved in stress response dysregulation and exploring targeted therapeutic strategies. While no disease\u2010modifying therapies are available, guidelines emphasize multidisciplinary management including neurologic, endocrine, and rehabilitative support, while special considerations are in place for hormonal treatment in patients considering pregnancy or lactation.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Newly diagnosed huntington patient asking that he does not want to inform his employee, what you will do?",
    "option_a": "Document this in his papers and respect the patient wish.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "The core concept in this scenario is patient confidentiality and respect for patient autonomy. When a patient expresses a desire to keep certain aspects of their health information private, such as their Huntington's diagnosis from their employer, the physician\u2019s duty is to maintain confidentiality unless there is a compelling reason (such as imminent harm to self or others) to breach it. Huntington\u2019s disease is a progressive, autosomal dominant neurodegenerative disorder characterized by choreiform movements, cognitive decline, and psychiatric symptoms. While the biology of the disease is significant for patient management, it does not alter the ethical principle of confidentiality in disclosing sensitive information. Patients with Huntington\u2019s disease often face social stigma and possible discrimination. The patient\u2019s request not to inform his employer reflects fears of such negative consequences. Respecting this request is important in maintaining trust and promoting a therapeutic relationship. Diagnosis of Huntington\u2019s is based on clinical findings (movement disorders, cognitive changes, psychiatric symptoms) along with genetic testing. However, regardless of the diagnosis, disclosure of this information to third parties like employers without patient consent is ethically inappropriate. The latest guidelines on patient confidentiality emphasize respecting patient wishes. The primary management is to document the patient\u2019s decision in his medical records and provide counseling on potential future implications. In scenarios involving potential risks or legal mandates, physicians may need to reconsider but only after a careful ethical assessment. For patients who are pregnant or lactating (although not directly applicable here), it is similarly critical to respect patient autonomy regarding disclosure of diagnoses while ensuring appropriate support. Option A correctly reflects the ethical and legal obligation to respect the patient's wishes by maintaining confidentiality and documenting his decision. Other options (B, C, D) are not provided, but none would supersede the need for confidentiality unless there were overriding legal or safety concerns. 1. Patient confidentiality is a cornerstone of medical ethics. 2. Disclosure of a diagnosis to third parties requires explicit patient consent unless there is a clear indication of harm. Recent ethical guidelines and consensus statements from bodies like the American Medical Association (AMA) and other regulatory authorities reinforce that patient information is strictly confidential, and disclosures should only occur with the patient's informed consent or under exceptional circumstances.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Schezophrenia Patient unable to sit, on antipsychotic, Dx?",
    "option_a": "chorea",
    "option_b": "tics",
    "option_c": "Akathesia",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Movement Disorders",
    "explanation": "This question addresses the recognition of antipsychotic-induced extrapyramidal side effects, specifically akathisia, a common adverse effect seen in patients on antipsychotic medications. Akathisia is thought to result from dopamine D2 receptor blockade in the nigrostriatal pathway, leading to an imbalance in neurotransmitter systems that manifest as inner restlessness and motor agitation. Recent research supports a role for both dopaminergic and serotonergic dysfunction in akathisia\u2019s pathobiology. Clinically, patients report a subjective sense of inner restlessness and find it difficult to remain seated. This can manifest as an inability to sit still, pacing, or constant fidgeting, which is distressing and can impact compliance with treatment. Key differentials include acute dystonic reactions (which are usually painful, sustained muscle contractions), tardive dyskinesia (characterized by repetitive, involuntary movements often involving the face and tongue), and other movement disorders like chorea. A careful review of the medication history, timing of symptom onset relative to drug initiation, and detailed neurological examination help in differentiating these conditions. First-line management typically includes beta-blockers (such as propranolol) which are well-supported by current guidelines. Benzodiazepines like lorazepam or anticholinergic agents may be considered as alternatives depending on patient-specific factors. In pregnant or lactating patients, the use of beta-blockers is generally cautious and requires assessing risks versus benefits, with propranolol being used after careful consideration of fetal impacts. Option A (Chorea) and Option B (Tics) are not consistent with the typical presentation of persistent restlessness. Option C, Akathisia, correctly identifies the movement disorder characterized by an inability to sit still. Option D is not provided, but among the given, C is the correct diagnosis. 1. Akathisia is a common and distressing side effect of antipsychotic medications that can affect medication adherence. 2. The onset of akathisia can be early in the course of treatment, and recognition is key to prompt management. Recent clinical practice guidelines emphasize the recognition and management of antipsychotic-induced akathisia, with beta-blockers being the treatment of choice. Updated reviews continue to support the efficacy and safety of these agents, while also underscoring the need to monitor for cardiovascular side effects, especially in special populations such as pregnant women.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "30 yrs old female patient presented with parkinsonism, and worsening dystonia. She had similar presentation 10 yrs ago and improved with levodopa, came today to the clinic what you will give her?",
    "option_a": "Levodopa",
    "option_b": "Dopamin agonist",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "This question revolves around recognizing a dopa-responsive movement disorder, where a young patient with parkinsonism and dystonia exhibits a dramatic response to levodopa. Dopa-responsive dystonia (often referred to as Segawa syndrome) is typically due to a deficit in dopamine synthesis, frequently linked to a mutation affecting the enzyme GTP cyclohydrolase I. This leads to decreased dopamine levels in the basal ganglia and manifests as both dystonic and parkinsonian features. Patients often present at a young age with a combination of dystonia (often worsening as the day progresses) and parkinsonian signs. A hallmark of the condition is the robust and sustained improvement with low doses of levodopa, which helps differentiate it from other movement disorders. Diagnosis is primarily clinical, based on the patient\u2019s history, examination, and the dramatic response to a trial of levodopa. Differential diagnoses include early-onset Parkinson's disease and other forms of dystonia such as Wilson\u2019s disease. Neuroimaging and laboratory tests may be used to rule out alternative causes. Levodopa is the first-line treatment and typically produces a dramatic improvement in symptoms. Dopamine agonists are generally not first-line in this syndrome. In the context of pregnancy or lactation, levodopa is used cautiously; while data are limited, many clinicians continue levodopa if the benefits outweigh the risks, with close monitoring and interdisciplinary management involving neurology and obstetrics. Option A, Levodopa, is correct as the patient\u2019s history of previous improvement with this medication strongly supports a diagnosis of dopa-responsive dystonia. Option B, dopamine agonists, are less effective in this condition and are not the established first-line therapy. 1. A dramatic response to low-dose levodopa is pathognomonic for dopa-responsive dystonia. 2. Onset in childhood or early adulthood with diurnal variation in symptoms is characteristic. Current clinical guidelines and recent studies continue to affirm levodopa as the gold standard treatment for dopa-responsive dystonia, with evidence showing sustained clinical benefit and a favorable safety profile even over long durations of therapy.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Schezophrenia on antipsychotic came with orolingual dystonia, what is the Dx?",
    "option_a": "Tardive Dyskinesia.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "This question highlights the identification of neuroleptic-induced movement disorders. Orolingual dyskinetic movements in a patient on long-term antipsychotic therapy are a classic presentation of tardive dyskinesia. Tardive dyskinesia is believed to result from chronic dopamine receptor blockade, which leads to upregulation and supersensitivity of dopamine receptors in the basal ganglia. This receptor hypersensitivity causes the involuntary, often repetitive movements affecting the orofacial region. Patients typically present with involuntary, repetitive movements of the lips, tongue, and facies. These movements are often subtle in the early stages but may progress to significant facial dyskinesia. The condition is generally seen in individuals who have been on antipsychotic medications for a prolonged period. The diagnosis is clinical, based on the history of prolonged antipsychotic use and the characteristic orofacial movements. Differential diagnoses include acute dystonic reactions (which usually occur soon after starting therapy and are painful and sustained) and other movement disorders such as tardive dystonia versus tardive dyskinesia. A detailed drug history and clinical examination are essential to differentiate them. Management includes reducing or discontinuing the offending antipsychotic, when possible, or switching to an atypical antipsychotic with a lower risk profile. Newer agents such as VMAT2 inhibitors (e.g., valbenazine, deutetrabenazine) have been approved for the treatment of tardive dyskinesia. In pregnant or lactating patients, therapeutic decisions must balance the risks of ongoing antipsychotic therapy with the potential teratogenic or neonatal effects, necessitating a careful, multidisciplinary approach. Option A, Tardive Dyskinesia, is the correct diagnosis given the description of orolingual involuntary movements in a patient on antipsychotics. Other options (such as tics or acute dystonia) do not typically present as orofacial dyskinesias associated with long-term antipsychotic use. 1. Tardive dyskinesia is often irreversible, which highlights the importance of early detection and management. 2. Regular screening for movement disorders in patients on long-term antipsychotic therapy is essential. Recent research and updated guidelines emphasize the utility of VMAT2 inhibitors for managing tardive dyskinesia and stress the importance of routine monitoring of patients on antipsychotics. Studies continue to evaluate the risk\u2013benefit profile of various antipsychotics with a focus on reducing the incidence of tardive syndromes.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Patient with HTN, DM with hx of CABG; presented with bilateral lower limbs slowing, and parkinsonism; MRI leukoariosis and hydrocephalus exvacua, what you will do?",
    "option_a": "VP shunt",
    "option_b": "treat his vascular risk factors",
    "option_c": "start levodopa",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Movement Disorders",
    "explanation": "This case describes a patient with vascular risk factors (hypertension, diabetes, history of CABG) presenting with lower limb slowing and parkinsonism. In such patients, vascular parkinsonism\u2014a form of parkinsonian syndrome resulting from cerebrovascular disease\u2014is a common consideration. The MRI findings (leukoaraiosis and hydrocephalus ex vacuo) point to chronic small vessel ischemic changes and atrophy rather than a treatable hydrocephalus. Chronic small vessel ischemia leads to white matter changes (leukoaraiosis) which disrupt the neural pathways involved in gait and motor control. Hydrocephalus ex vacuo occurs when brain atrophy makes the ventricles appear enlarged, but the enlargement is secondary to tissue loss rather than increased CSF pressure. Vascular damage in regions that modulate motor function results in a clinical syndrome similar to parkinsonism, though it does not generally respond to dopaminergic therapy. The patient\u2019s clinical picture\u2014with bilateral lower limb slowness and parkinsonian features in the setting of longstanding vascular risk factors\u2014is more consistent with vascular parkinsonism. The imaging provides evidence of chronic ischemic changes rather than the pattern seen in normal pressure hydrocephalus (which has a triad of gait disturbance, urinary incontinence, and cognitive decline and is potentially treatable with a VP shunt). Key differentials include idiopathic Parkinson\u2019s disease, normal pressure hydrocephalus (NPH), and multi-infarct/dysexecutive syndrome. Distinguishing features include: (1) NPH usually presents with gait apraxia, urinary incontinence, and cognitive impairment with improved symptoms post-large-volume lumbar puncture; (2) Idiopathic Parkinson\u2019s disease typically responds to dopaminergic therapy and has asymmetrical onset; (3) Vascular parkinsonism shows lower body predominance with imaging evidence of vascular disease. The primary management is to aggressively control vascular risk factors (ie, hypertension, diabetes, hyperlipidemia) to prevent further cerebrovascular damage. In this context, dopaminergic therapy (levodopa) is typically less effective. Shunting (VP shunt) is reserved for true cases of normal pressure hydrocephalus, not for hydrocephalus ex vacuo. Pregnancy and lactation considerations involve selecting antihypertensives and antidiabetic medications that are safe; for example, labetalol or methyldopa for hypertension in pregnancy. Option A (VP shunt) is incorrect because hydrocephalus ex vacuo is not a form of CSF accumulation amenable to shunting. Option B (Treat his vascular risk factors) is correct as it addresses the underlying cause. Option C (Start levodopa) is not typically beneficial in vascular parkinsonism, as the dopaminergic deficit differs from that in idiopathic Parkinson\u2019s disease. 1. Vascular parkinsonism often presents with predominant lower-body involvement and gait difficulties. 2. Hydrocephalus ex vacuo is due to brain atrophy and does not improve with shunting. 3. MRI findings of leukoaraiosis in a patient with vascular risk factors support a diagnosis of vascular parkinsonism. Recent studies emphasize the importance of optimal management of vascular risk factors to slow progression of white matter changes and gait instability. Advanced imaging techniques have improved differentiation between vascular parkinsonism and other disorders like NPH, guiding appropriate treatment decisions.",
    "exam_year": "2021",
    "exam_type": "Part II"
  }
]